HC Wainwright & Co. Reiterates Neutral on Kyverna Therapeutics, Maintains $7 Price Target
H.C. Wainwright Maintains Kyverna Therapeutics(KYTX.US) With Hold Rating, Maintains Target Price $7
H.C. Wainwright analyst Mitchell Kapoor maintains $Kyverna Therapeutics(KYTX.US)$ with a hold rating, and maintains the target price at $7.According to TipRanks data, the analyst has a success rate
Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024
Kyverna Therapeutics Announces Leadership Update, Warner Biddle Appointed As Chief Executive Officer, Succeeds Peter Maag, Who Has Resigned From His Role As Ceo And A Member Of The Board, Effective Immediately
Express News | Kyverna Therapeutics Inc - Peter Maag Resigns as CEO of Kyverna Therapeutics
Express News | Kyverna Therapeutics Inc - Appoints Warner Biddle as CEO
Press Release: Kyverna Therapeutics Announces Leadership Update
J.P. Morgan Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $33
J.P. Morgan analyst Brian Cheng maintains $Kyverna Therapeutics(KYTX.US)$ with a buy rating, and maintains the target price at $33.According to TipRanks data, the analyst has a success rate of 34.4%
Kyverna Therapeutics to Participate in Upcoming September Investor Conferences
Toll Brothers Posts Strong Earnings, Joins Keysight, Coty, TJX And Other Big Stocks Moving Higher On Wednesday
Kyverna Therapeutics Is Maintained at Neutral by HC Wainwright & Co.
H.C. Wainwright Initiates Kyverna Therapeutics(KYTX.US) With Hold Rating, Announces Target Price $7
H.C. Wainwright analyst Mitchell Kapoor initiates coverage on $Kyverna Therapeutics(KYTX.US)$ with a hold rating, and sets the target price at $7.According to TipRanks data, the analyst has a
Analysts Offer Insights on NA Companies: Kyverna Therapeutics, Inc. (KYTX), Smith Douglas Homes Corp. Class A (SDHC) and Kayne Anderson BDC, Inc. (KBDC)
Express News | Kyverna Therapeutics Inc : H.c. Wainwright Cuts Target Price to $7 From $8
Kyverna Therapeutics GAAP EPS of -$0.67
Home Depot, Paysafe And 3 Stocks To Watch Heading Into Tuesday
Kyverna Therapeutics Says FDA Grants Regenerative Medicine Advanced Therapy Designation to Autoimmune Disorder Drug
Express News | Kyverna Therapeutics Inc - Qtrly Shr Loss $0.67
Kyverna Therapeutics Q2 EPS $(0.67) Misses $(0.64) Estimate
Kyverna Therapeutics | 10-Q: Quarterly report